1[1]Crozier I,Ikram H,Awan N,et al.Losartan in heart failure hemodynamic effects and tolerability [J]. Circulation, 1995,91 (3):691-697.
2[2]Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure[J]. Lancet,1997,349(9054) :747-752.
3[3]Kabour A, Henegar JR,Devineni VR, et al. Prevention of angiotensin Ⅱ induced myocyte necrosis and coronary vascular damage bylisinopril and losartan in the rat[J]. Cardiovasc Res, 1995,29(4) :543-548.
4[4]Basu S, Senior R, Raval U, et al. Beneficial effects of intravenous and oral carvedilol treatment in acute rnyocardial infarction. A placebo-controlled, randomized trial[J]. Circulation, 1997,96(1):183-191.
5[5]Brunvand H, Kvitting PM,Rynning SE, et al. Carvedilol protects against lethal reperfusion injury through antiadrenergic mechanisms[J]. Cardiovasc Pharmacol, 1996,28(3) :409-417.
6[6]Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger[J]. J Pharmacol Exp Ther, 1992,263 ( 1 ) : 97-98.
